• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Seven Tumor Types: Pros and Cons

Video

Unlike the Oncology Care Model, the Enhancing Oncology Model will focus on 7 common cancer types, which experts say offers advantages and disadvantages for practices.

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, led a discussion on a pros and cons of limiting the Enhancing Oncology Model (EOM) to 7 common cancer types. Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, agreed that honing in common cancers could lead to better predictability in cost of care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, raised concerns that lack of monthly payments for other cancer types for harm practices giving patients supportive services; Divers and Schleicher concurred on the potential effects on quality.

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
"Integrating New PAH Therapies into Clinical Practice"
Julie Patterson, PharmD, PhD
"Clinical Evidence for Emerging PAH Therapies"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.